Medicare AdvantagePrior AuthMedium impact
Welireg (belzutifan) (Revised)
Humana·Oncology, Internal Medicine·Medicare Advantage
Effective date
May 27, 2026
We identified it
Jun 25, 2026
Summary
Humana updated its prior authorization policy for Welireg (belzutifan) effective May 27, 2026. The policy covers three indications for Medicare Advantage members: von Hippel Lindau (VHL) disease with associated tumors, advanced renal cell carcinoma (RCC) after prior treatment failure, and pheochromocytoma/paraganglioma (PPGL) in patients 12 years and older. All approvals require monotherapy administration and prior authorization before dispensing.
Action Required
By May 27, 2026: Billing and prior authorization teams must implement new claim routing and authorization requirements for Welireg (belzutifan). (1) Update billing system to flag all Welireg claims for mandatory prior authorization review before submission. (2) Configure system to verify three separate authorization pathways: VHL disease patients (requires confirmation of non-surgical status and associated RCC/CNS hemangioblastomas/pancreatic NET), RCC patients (requires documentation of prior PD-1/PD-L1 AND VEGF-TKI failure), and PPGL patients (requires confirmation of age 12+). (3) Ensure all three indications are set to require monotherapy confirmation—reject authorizations if combination therapy is documented. (4) Train prior auth staff that disease progression on Welireg is an exclusion triggering denial. (5) Set authorization duration to plan year for initial and renewal approvals. (6) Update internal documentation requirements to match criteria for each indication. (7) Educate oncology providers that this is a new revision and previous authorization templates may not align. Failure to obtain prior authorization will result in claim denials for all Welireg prescriptions under Humana Medicare Advantage plans.